

April 24, 2013

Dear Physician(s) & Staff,

As part of completing the transition to an upgraded automated multi-channel analyzer (Roche Cobas system), Enzo Clinical Labs will be changing a tumor marker assay for monitoring breast cancer response to therapy. Enzo currently uses the Siemens proprietary CA 27.29 marker, but we will be moving to an equivalent marker, CA 15-3, on the Roche instrument. While these two assays correlate extremely well, their absolute values will vary since each assay uses different antibodies to detect different parts of the same peptide marker.

Unless you indicate differently, effective May 6th 2013, we will convert all future CA 27.29 orders to CA 15-3 testing.

If you would like to continue testing CA 27.29, we would like to offer you the chance to have the 2 assays run at the same time on the patients you are monitoring for breast cancer follow up. Before May 6th, when we officially go live with the new instrument, we can run these 2 assays simultaneously on the Siemens and Roche analyzers at Enzo. After May 6th, we can send a sample out to a reference lab for CA 27.29 and perform the CA 15-3 testing in-house on the new analyzer. For the first two (2) patient comparisons, we will not charge your patients for the additional testing. If you would like to participate in this patient comparison or "re-base lining", please let your sales representative know, and we will work with you to perform the testing.

Current Test	CA 27.29	1 mL Serum	Normal cutoff ≤ 38.6 U/mL
Replacement Test:	CA 15-3	1 mL Serum	Normal cutoff <25 U/mL

If you have any questions or comments, please contact your Enzo sales/service representative or call Deborah Esposito, Technical Director, at 631-755-5500, Ext. 276.

Sincerely,



Cynthia M. Bowman, MD
Medical Director
Enzo Clinical Labs